Novartis has launched two new construction projects to bolster its manufacturing and supply network for its radioligand therapies for cancer patients.
The company broke ground on a new manufacturing facility at its site in Indianapolis, Indiana, to establish in-house production of isotopes for radioligand therapies, and launched plans for a new manufacturing facility in Carlsbad, California. The facilities will create resiliency in the company’s manufacturing network and optimize delivery of the medicines to patients on the U.S. West Coast, Novartis said.
Following regulatory approvals, isotopes produced in Indianapolis will be used to manufacture lutetium-177 (Lu-177) PSMA-617 (Pluvicto), Lu-177 DOTATATE (Lutathera), and investigational radioligand therapies in the company’s pipeline.
